Abstract
Caspofungin is a member of the echinocandin class of antifungal compounds that inhibit 1,3-β-d-Glucan synthase. As patient exposure to caspofungin (CAS) broadens, the number of infecting strains with reduced susceptibility to this drug is expected to rise. In the present study, the in vitro effects of varying concentrations of CAS against Candida albicans isolates presenting reduced susceptibility to CAS were studied in comparison with a reference strain. Two C. albicans isolates presenting high minimal inhibitory concentrations (MIC = 8 μg ml(-1) ) were selected: one isolate obtained in the laboratory under continuous antifungal selection pressure (CaIn-R) and one clinical isolate (CaClin-R) from a patient with a therapeutic failure. Results showed that after 24 h of CAS exposure, CaIn-R and CaClin-R presented a partial growth inhibition in comparison with the reference strain. Moreover, scanning electron microscopy and transmission electron microscopy studies showed that the cell walls of CaIn-R and CaClin-R were less altered than that of the reference strain. These observations suggested that although CaIn-R and CaClin-R cells were misshapen after CAS exposure, cell lysis was limited after 24 h of treatment indicating higher...Continue Reading
References
Dec 1, 1988·The Journal of Antimicrobial Chemotherapy·F C Odds
Nov 29, 2001·Journal of Clinical Microbiology·M A PfallerR N Jones
Dec 4, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S AsciogluUNKNOWN Mycoses Study Group of the National Institute of Allergy and Infectious Diseases
Sep 14, 2002·Journal of Electron Microscopy·Yayoi NishiyamaHideyo Yamaguchi
Dec 20, 2002·The New England Journal of Medicine·Jorge Mora-DuarteUNKNOWN Caspofungin Invasive Candidiasis Study Group
Mar 5, 2003·The Journal of Antimicrobial Chemotherapy·Valérie Letscher-Bru, Raoul Herbrecht
Apr 26, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hilmar WisplinghoffMichael B Edmond
May 27, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stanley C Deresinski, David A Stevens
Apr 16, 2004·Clinical Microbiology Reviews·James Masuoka
Aug 26, 2004·Antimicrobial Agents and Chemotherapy·David A StevensRachana Parmar
Mar 9, 2005·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·J A M S JayatilakeL P Samaranayake
Aug 30, 2005·Antimicrobial Agents and Chemotherapy·Nicholas KartsonisMary Motyl
Jan 21, 2006·FEMS Yeast Research·José Ruiz-HerreraRafael Sentandreu
Aug 31, 2006·Antimicrobial Agents and Chemotherapy·David A StevensHiroyuki Horiuchi
Oct 6, 2006·Journal of Clinical Microbiology·M A PfallerD J Diekema
Jan 16, 2007·Clinical Microbiology Reviews·M A Pfaller, D J Diekema
Jun 16, 2007·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·David S Perlin
Jun 27, 2008·Journal of Clinical Microbiology·M A PfallerT J Walsh
Citations
Jan 16, 2013·Infection and Immunity·Michael J LinkeMelanie T Cushion
Apr 14, 2011·European Journal of Medical Research·Andreas Glöckner
Oct 16, 2015·Biointerphases·Stefani S GriesserHans J Griesser
Dec 25, 2012·Nanoscale·Sofiane El-Kirat-ChatelYves F Dufrêne
Sep 9, 2017·Nanoscale·Fabienne QuilèsSofiane El-Kirat-Chatel
Nov 6, 2020·MSphere·Arzu ÇolakMehmet Z Baykara